

LIST OF TABLES

Table no.	Table Title	Page no.
Table 1.4.1	Dosage form introduction into market for MS and MH	7
Table 2.1.1	Review of work done on MUPS	13
Table 2.4.1	Review of work done on Oral Powder for Reconstitution	32
Table 2.4.2	Review of work done on Orally Disintegrating Tablet	34
Table 2.7.1	Physicochemical and biopharmaceutical properties of MS	41
Table 2.7.2	Review of work done on Metoprolol Succinate	43
Table 2.7.3	Metoprolol Succinate formulations with their introduction year	46
Table 2.7.4	Physicochemical and biopharmaceutical properties of MH	46
Table 2.7.5	Review of work done on Metformin Hydrochloride	49
Table 2.7.6	Metformin Hydrochloride formulations and their introduction year	52
Table 3.4.1	Calibration data for MS at 274 nm in various solvents	68
Table 3.4.2	Linear regression analysis of calibration data for MS in different solvents	68
Table 3.4.3	Absorbance data of MS at 0 and 24 h for analytical stability	70
Table 3.4.4	Intraday and Interday Precision Analysis of UV Method for MS	72
Table 3.4.5	Standard addition data to measure accuracy of UV Method in Different Solvents	73
Table 3.4.6	LOD and LOQ calculation from calibration data of MS in different solvents	73
Table 3.4.7	Specificity and interference study of formulation components for MS	74
Table 3.4.8	Calibration data for MS by HPLC	76
Table 3.4.9	Absorbance data of MS at 0 and 24 h for analytical stability	77
Table 3.4.10	Intraday and Interday Precision Analysis of HPLC Method	78
Table 3.4.11	Standard addition data to measure accuracy of HPLC method for MS	79
Table 3.4.12	LOD and LOQ calculation from calibration curve of MS by HPLC	79
Table 3.4.13	UV spectrophotometric calibration data for MH	81

Table 3.4.14	Linear regression analysis of calibration data for MH in different solvents	81
Table 3.4.15	Absorbance data of MH at 0 and 24 h for analytical stability	83
Table 3.4.16	Intraday and Interday Precision Analysis of UV Method for MH	85
Table 3.4.17	Standard addition data to measure accuracy of UV Method in different solvents	86
Table 3.4.18	LOD and LOQ calculation from calibration data of MH in different solvents	86
Table 3.4.19	Specificity and Interference study of formulation components for MH	87
Table 3.4.20	Calibration data for MH by HPLC	88
Table 3.4.21	Absorbance data of MH at 0 and 24 h for analytical stability	89
Table 3.4.22	Intraday and Interday Precision Analysis of HPLC method for MH	90
Table 3.4.23	Standard addition data to measure accuracy of HPLC method for MH	91
Table 3.4.24	LOD and LOQ calculation from calibration curve of MH by HPLC	91
Table 4.1.1	List of Equipments and Instruments	94
Table 4.3.1	QTPP for MS and MH controlled release pellets	98
Table 4.3.2	Drug release as QTPP element for MS and MH controlled release pellets	98
Table 4.3.3	Initial Formulation Risk Assessment for MS and MH MUPS	99
Table 4.3.4	Selection of load	100
Table 4.3.5	Composition used for selection of MS loading process parameters	101
Table 4.3.6	Selection of process parameters for MS loading	102
Table 4.3.7	Composition used for selection of MH loading process parameters	102
Table 4.3.8	Selection of process parameters for MH loading	102
Table 4.3.9	Selection of solid content for MS loading solution	104
Table 4.3.10	Selection of solid content for MH loading solution	104
Table 4.3.11	Selection of binder in MS loading stage	105
Table 4.3.12	Selection of binder in MH loading stage	106
Table 4.3.13	Optimization of binder concentration in MS loading stage	107

Table 4.3.14	Optimization of binder concentration in MH loading stage	108
Table 4.3.15	Composition for selection of MS-CR coating process parameters	109
Table 4.3.16	Selection of processing variables for MS-CR coating stage	109
Table 4.3.17	Composition for selection of MH-CR coating process parameters	109
Table 4.3.18	Selection of processing variables for MH-CR coating stage	109
Table 4.3.19	Selection of solid content for MS-CR coating stage	110
Table 4.3.20	Selection of solid content for MH-CR coating stage	111
Table 4.3.21	Selection of core pellet size for MS	112
Table 4.3.22	Selection of core pellet size for MH	113
Table 4.3.23	Selection of core pellet quantity per unit for MS	114
Table 4.3.24	Selection of core pellet quantity per unit for MH	115
Table 4.3.25	Selection of CR polymer for MS	116
Table 4.3.26	Selection of CR polymer for MH	117
Table 4.3.27	Drug loading by reservoir technique for MS	118
Table 4.3.28	Process parameters for reservoir technique (Batch MS-25)	118
Table 4.3.29	Drug loading by reservoir technique for MH	119
Table 4.3.30	Process parameters for reservoir technique (Batch MH-23)	119
Table 4.3.31	MS loading by matrix technique	121
Table 4.3.32	Process parameters for matrix technique (Batch MS-31)	121
Table 4.3.33	MH loading by matrix technique	121
Table 4.3.34	Process parameters for matrix technique (Batch MH-25)	122
Table 4.3.35	Optimization for extent of CR coating and drug: polymer ratio for MS matrix system	123
Table 4.3.36	Process parameters for optimization of extent of CR coating and drug: polymer ratio for MS matrix system	123
Table 4.3.37	Optimization for extent of CR coating and drug: polymer ratio for MH matrix system	124

Table 4.3.38	Process parameters for optimization of extent of CR coating and drug: polymer ratio for MH matrix system	124
Table 4.3.39	Independent variables (factors) and their levels for MS-FCCD	126
Table 4.3.40	Independent variables (factors) and their levels for MH-FCCD	126
Table 4.3.41	Composition for selection of process parameters for MS-Eudragit® E coating	128
Table 4.3.42	Process parameters for MS-Eudragit® E coating	128
Table 4.3.43	Composition for selection of process parameters for MH-Eudragit® E coating	129
Table 4.3.44	Process parameters for MH-Eudragit® E coating	129
Table 4.3.45	Selection of solid content for Eudragit® E coating	130
Table 4.3.46	Selection of solid content for Eudragit® E coating	131
Table 4.3.47	Scale of flowability	133
Table 4.3.48	Flow properties and corresponding angle of repose	134
Table 4.4.1	Functional groups along with their wave numbers for Metoprolol succinate	140
Table 4.4.2	Functional groups along with their wave numbers for Metformin hydrochloride	140
Table 4.4.3	Physical compatibility study of MS with excipients	142
Table 4.4.4	Physical compatibility study of MH with excipients	143
Table 4.4.5	Principal peaks in IR spectra (MS)	147
Table 4.4.6	Principal peaks in IR spectra (MH)	147
Table 4.5.1	Risk assessment by FMEA analysis to identify criticality of failure modes	149
Table 4.5.2	Selection of load for MUPS	151
Table 4.5.3	Selection of process parameters for MS loading	152
Table 4.5.4	Selection of process parameters for MH loading	152
Table 4.5.5	Selection of solid content for MS loading solution	154
Table 4.5.6	Selection of solid content for MH loading solution	154
Table 4.5.7	Results for binder selection batches for MS	155
Table 4.5.8	Results for binder selection batches for MH	156

Table 4.5.9	Results for optimization of binder concentration	156
Table 4.5.10	Results for optimization of binder concentration for MH	157
Table 4.5.11	Results for percentage yield for CR coating stage of MS MUPS	158
Table 4.5.12	Results for percentage yield for CR coating stage of MH MUPS	158
Table 4.5.13	Results for selection of solid content for CR coating stage of MS MUPS	159
Table 4.5.14	Results for selection of solid content for CR coating stage of MH MUPS	159
Table 4.5.15	Results for selection of core pellet size for MS MUPS	160
Table 4.5.16	Results for selection of core pellet size for MH MUPS	162
Table 4.5.17	Results for selection of core pellet quantity per unit for MS	163
Table 4.5.18	Results for selection of core pellets quantity per unit for MH	164
Table 4.5.19	Results for selection of CR polymer batches for MS	166
Table 4.5.20	Results for selection of CR polymer batches for MH	167
Table 4.5.21	Batches prepared with Reservoir and Matrix techniques-MS	170
Table 4.5.22	Batches prepared with Reservoir and Matrix techniques-MH	171
Table 4.5.23	Optimization for solid content of coating solution for MS matrix system	174
Table 4.5.24	Optimization for solid content of coating solution for MH matrix system	174
Table 4.5.25	Results for optimization of extent of CR coating and drug: polymer ratio -MS matrix system	175
Table 4.5.26	Results for optimization of extent of CR coating and drug: polymer ratio - MH matrix system	177
Table: 4.5.27	Results for curing study of MS MUPS	179
Table: 4.5.28	Results for curing study of MH MUPS	180

Table 4.5.29	Design matrix for MS MUPS-CCF along with observed response values for matrix system	182
Table 4.5.30	Design matrix for MH MUPS-CCF along with observed response values for matrix system	183
Table 4.5.31	Final Formulation Risk Assessment for MS and MH MUPS	193
Table: 4.5.32	Selection of process parameters for MS Eudragit® E coating trials	194
Table: 4.5.33	Percentage yield for selection of process parameters for MH Eudragit® E coating trials	194
Table 4.5.34	Selection of solid content for MS-Eudragit® E coating	195
Table 4.5.35	Selection of solid content for MH-Eudragit® E coating	196
Table 4.5.36	Drug release profile for optimized MS-Eudragit® E coated pellets (Batch MS-40)	203
Table 4.5.37	Drug release profile for optimized MS-Eudragit® E coated pellets (Batch MH-33)	203
Table 4.5.38	Linear correlation coefficient values of various models for in vitro release study	203
Table 5.1.1	List of Equipments and Instruments	209
Table 5.2.1	Selection of suspending agent for MS-CRPFR	211
Table 5.2.2	Selection of suspending agent for MH-CRPFR	212
Table 5.2.3	Selection of alkalizer for MS-CRPFR	213
Table 5.2.4	Selection of alkalizer for MH-CRPFR	213
Table 5.2.5	Batches for minimization of MS leaching	215
Table 5.2.6	Batches for minimization of MH leaching	216
Table 5.3.1	Results for stability studies of MS-CRPFR	222
Table 5.3.2	Results for stability studies of MH-CRPFR	223
Table 5.4.1	List of Equipments and Instruments	225
Table 5.5.1	Selection of superdisintegrants for MS-CRODT	227
Table 5.5.2	Selection of superdisintegrants for MH-CRODT	228

Table 5.5.3	Selection of diluent for MS-CRODT	229
Table 5.5.4	Selection of diluent for MH-CRODT	230
Table 5.5.5	Optimization of super disintegrant level to achieve fast disintegration for MS-CRODT	231
Table 5.5.6	Optimization of super disintegrant level to achieve fast disintegration for MH-CRODT	231
Table 5.5.7	Optimization of cushioning agent for prevention of rupture of MS pellets	232
Table 5.5.8	Optimization of cushioning agent for prevention of rupture of MH pellets	233
Table 5.6.1	IPQC tests for MS-CRODT	235
Table 5.6.2	IPQC tests for MH-CRODT	235
Table 5.6.3	IPQC tests for MS-CRODT	236
Table 5.6.4	IPQC tests for MH-CRODT	236
Table 5.6.5	IPQC tests for MS-CRODT	237
Table 5.6.6	IPQC tests for MH-CRODT	237
Table 5.6.7	Drug release study for optimization of super disintegrant level-MS	237
Table 5.6.8	Drug release study for optimization of super disintegrant level-MH	238
Table 5.6.9	Results of in process tests for MS-CRODT	241
Table 5.6.10	Results of in process tests for MH-CRODT	241
Table 5.6.11	Results for optimization of cushioning agent and prevention of rupture of MS- pellets	241
Table 5.6.12	Results for optimization of cushioning agent and prevention of rupture of MH- pellets	242
Table 5.6.13	Results for stability studies of Batch MS-T11	246
Table 5.6.14	Results for stability studies of Batch MH-T12	247
Table 6.3.1	Plasma concentration profiles of orally administered MS formulations in rabbits	251
Table 6.3.2	Pharmacokinetic parameters of orally administered MS formulations	252

Table 6.3.3	Plasma concentration profiles of orally administered MH formulations in rabbits	253
Table 6.3.4	Pharmacokinetic parameters of orally administered MH formulations	254